Use of exosomes for the treatment of disease

Patent metadata

Field	Value
Publication number	US-10959952-B2
Application number	US-201816203265-A
Country	US
Kind code	B2
Filing date	Nov 28, 2018
Priority date	Jun 10, 2015
Publication date	Mar 30, 2021
Grant date	Mar 30, 2021

Abstract

The present invention provides lipid-based nanoparticles (e.g., liposomes or exosomes) having CD47 on their surface and comprising a therapeutic agent (e.g., a therapeutic protein, an antibody, an inhibitory RNA, and/or a small molecule drug). Furthermore, the present invention provides for use of such lipid-based nanoparticles in therapy.

First claim

What is claimed is:

1. A pharmaceutical composition comprising an exosome and an excipient, wherein the exosome comprises an inhibitory RNA selected from the group consisting of a siRNA, shRNA, miRNA, and pre-miRNA, wherein the exo some is isolated from a normal skin fibroblast cell that overexpresses CD47, and wherein the exosome comprises CD47 on its surface.

2. The composition of claim 1 , wherein the composition is formulated for parenteral administration.

3. The composition of claim 2 , wherein the composition is formulated for intravenous, intramuscular, sub-cutaneous, or intraperitoneal injection.

4. The composition of claim 2 , further comprising an antimicrobial agent.

5. The composition of claim 4 , wherein the antimicrobial agent is selected from the group consisting of benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, centrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, exetidine, imidurea, phenol, phenoxyethanol, phenylethl alcohol, phenlymercuric nitrate, propylene glycol, and thimerosal.

6. The composition of claim 1 , wherein the inhibitory RNA is an siRNA.

7. The composition of claim 6 , wherein the siRNA is about 19 to about 25 nucleotides in length.

8. The composition of claim 6 , wherein the siRNA comprises a modified backbone.

9. The composition of claim 8 , wherein the siRNA comprises a phosphorothioate backbone or a phosphorodithioate backbone.

10. The composition of claim 6 , wherein the siRNA comprises one or more of a modification selected from the group consisting of a 2′-O-methyl ribonucleotide, a 2′-deoxy-2′-fluoro ribonucleotide, a “universal base” nucleotide, a 5-C-methyl nucleotide, a phosphorothioate internucleotide linkage, and an inverted deoxyabasic residue incorporation.

Assignees

• Univ Texas

Inventors

• Kalluri Raghu
• Melo Sónia

Classifications

• A61K31/7088 Primary

  Compounds having three or more nucleosides or nucleotides · CPC title

• A61K47/46

  Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C12N15/88

  using microencapsulation, e.g. using {amphiphile} liposome vesicle · CPC title

• A23L29/212

  Starch; Modified starch; Starch derivatives, e.g. esters or ethers (containing starch hydrolysates, e.g. dextrin, A23L29/30) · CPC title